Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
JPM Shares Slump Pre-Market After Client Activity Moderates -- WSJ

JPM Shares Slump Pre-Market After Client Activity Moderates -- WSJ

Dow JonesDow Jones2026/10/13 10:58

By Ben Glickman

Shares of the nation's largest bank were down over 3% in pre-market trading. Disappointing investment banking results seemed to be the culprit.

The stock was down 3.7% to about $322 a share.

CEO Jamie Dimon's commentary with results noted that IB and markets client "activity did moderate somewhat during the quarter."

The commercial and investment bank's revenue still rose 14% from a year ago, with investment banking feed and trading revenue both up too. But all were down from the second-quarter.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

October 13, 2026 06:58 ET (10:58 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss